What the Grey Market Costs

We track live inventory and pricing across roughly 31 grey-market vendors. Stripped to one number per molecule, here is what Chinese-origin peptides actually cost — not per vial, but per milligram of active, the only unit that lets you compare anything.

Figures are median prices across the 13 China-origin vendors that listed a standard 10-vial kit in the 30 days to June 2026 (9 to 12 vendors per compound). Methodology at the end. This documents an unregulated market; it is not an endorsement, and it is not dosing advice.

A vial price tells you almost nothing. A "$80 kit" of a 5mg peptide and a "$120 kit" of a 30mg peptide are not remotely comparable until you divide by the milligrams inside. So we did, across every recent China listing we hold, and reduced it to the going rate per milligram for the ten most widely stocked compounds.

The headline: this is now a commodity market, and it is priced like one. The blockbuster GLP-1s have collapsed toward cents per milligram, while the quiet research peptides — the ones that sound cheap by the vial — are what actually costs you. What the market actually charges:

The GLP-1 price war

Tirzepatide is the cheapest serious drug on the board at a median of $0.40 per milligram. Retatrutide, the newer and more hyped GLP-1, still carries a premium at $0.77 per milligram — roughly 2 times tirzepatide for the same delivery mechanism. That gap is the price of novelty, the kind that erodes as more factories bring a compound online. Semaglutide, the oldest of the three, sits between them. None of this tracks dose accuracy: as the certificate data shows, the GLP-1s are middle-of-the-pack on whether the vial actually holds its label.

The spread is the tax

The single most useful number on this page is not the median — it is the range. The same molecule, from different China vendors, in the same month, varies by as much as 6x for Semaglutide, and a 3-to-5x range is normal across the board. There is no quality story underneath most of that spread; it is simply what a vendor thinks it can charge. Buying from the wrong storefront is a self-inflicted tax of several hundred percent, and it is invisible until you put the prices side by side.

Cheap does not buy you the dose

It is tempting to read price as a quality signal — you get what you pay for. The data says otherwise, flatly. The cheapest categories per milligram carry some of the worst underdose rates we measure, and the mid-priced GLP-1s are among the better-dosed. Price and dose-accuracy are independent axes. A low number per milligram buys you a low number per milligram; whether the labeled dose is actually in the vial is a separate question that only a third-party test answers. That is the whole case for testing.

What the legal market charges

A grey-market number only means something next to the legal one. As of late 2025, brand tirzepatide bought self-pay direct from the manufacturer — Eli Lilly's single-dose Zepbound vials through LillyDirect — runs about $299 a month for the 2.5 mg starter dose, $399 for 5 mg, and $449 for every higher dose; compounded tirzepatide through a telehealth pharmacy runs roughly $125 to $399 a month. Put those in the same unit. At a common 10 mg weekly maintenance dose — about 40 mg a month — brand self-pay works out to roughly $11 per milligram, and the cheapest compounded options to about $3 to $10. The grey market sells the identical molecule for $0.40.

That is a ten-to-thirty-fold gap, and it is not all markup. The legal price buys a finished, sterile, identity-verified injectable made under inspection, plus a prescriber who is accountable for it. The grey-market price buys raw lyophilized powder in an unlabeled-strength vial, no oversight, and — as our certificate data shows — a coin flip on whether the dose on the label is even inside. The discount is real, but it is a risk premium you are choosing to carry yourself. The only way to convert any of it back into safety is to test what actually arrived.

Methods and limitations

Source. Every grey-market figure is computed live from our reconciled vendor pricelist table (deduped, kit-corrected, freshest-live-stock) filtered to origin_country = CHINA, standard 10-vial kits, listed in the last 30 days, across the 13 China vendors active in that window (of roughly 31 we track in total). Price per milligram = kit price / (10 vials x milligrams per vial). Listings dosed in IU or by volume, and multi-peptide blends, are excluded because they have no clean single-molecule milligram figure.

Why median, not average. We report the median, and it matters. Grey-market price data is right-skewed and pocked with extraction errors — a single mistyped or mis-parsed listing (a kit price recorded as a single vial) can read as ten times the real rate, and an average swallows that whole. The median does not move. Concretely, before cleaning, one tesamorelin row dragged the mean per-mg above $2.80 while the median sat near $1.80; the median was right. So we (1) drop any offering more than 3x off the compound's raw median as a parse error, (2) take each vendor's own median first, so a vendor listing many doses cannot dominate, then (3) report the median across vendors. After that cleaning the mean and median nearly converge, which is the signal that the noise is gone — but we keep the median as the headline because it answers the only question a buyer has: what does this typically go for. The mean answers a question nobody asked.

Legal-market reference prices are list/self-pay figures reported in late 2025 (Eli Lilly's LillyDirect Zepbound self-pay vials; reported telehealth compounded-pharmacy ranges) and are converted to a per-milligram basis at an illustrative 10 mg weekly dose — they are a different product class (finished sterile injectable, prescriber included) and are offered for scale, not as a like-for-like swap.

What this is not. A median is a snapshot of asking prices, not a recommendation, and a low price is not a safety claim. Cross-reference every number here against the dose-accuracy and purity data before it means anything. Every grey-market figure on this page regenerates directly from live vendor inventory; the queries are reproducible.